Sumitomo Mitsui Trust Group Inc. Trims Stock Holdings in IQVIA Holdings Inc. $IQV

Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 799,567 shares of the medical research company’s stock after selling 9,320 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in IQVIA were worth $151,870,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Asset Dedication LLC lifted its position in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $39,000. J.Safra Asset Management Corp boosted its holdings in IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the period. Hemington Wealth Management raised its holdings in shares of IQVIA by 43.4% during the third quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock worth $49,000 after purchasing an additional 79 shares during the period. Finally, Rothschild Investment LLC lifted its holdings in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Morgan Stanley lifted their target price on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and boosted their price target for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Finally, Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $249.19.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

IQV stock opened at $240.94 on Tuesday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The firm has a 50-day moving average of $224.91 and a two-hundred day moving average of $201.35. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $41.03 billion, a PE ratio of 33.05, a P/E/G ratio of 2.47 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.